Home › Funds › Affinity Asset Advisors, LLC › ARWR

Affinity Asset Advisors, LLC position in ARWR

ARROWHEAD PHARMACEUTICALS IN · Health Care

Affinity Asset Advisors, LLC reported holding 425,000 shares of ARWR (ARROWHEAD PHARMACEUTICALS IN) in its Q3 2026 13F filing — a position valued at US$27.8M, representing 1.30% of its reported portfolio and ranking #21 among its reported holdings. Affinity Asset Advisors, LLC has disclosed ARWR holdings in 8 of the last 11 reported quarters, going back to Q1 2024.

Latest position (Q3 2026)425.00K sh
Reported value held$27.82M
Portfolio Weight1.30%
First reportedQ1 2024
Last changeAdd
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Affinity Asset Advisors, LLC's ARWR position evolved

Affinity Asset Advisors, LLC first disclosed a stake in ARWR in Q1 2024 at 120,000 shares (US$3.4M). The position peaked in Q3 2026 at 425,000 shares, worth US$27.8M. Across 8 filings, Affinity Asset Advisors, LLC increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 425,000 shares valued at US$27.8M — an increase of 275,000 shares quarter over quarter.. Notable position changes include a 550% increase in Q3 2024 (shares fell 3% over the following quarter), a 186% increase in Q1 2026 (shares rose 30% over the following quarter), a 183% increase in Q3 2026 (shares fell 27% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 120.00K $3.43M New
Q2 2024 50.00K $1.30M Reduce
Q3 2024 325.00K $6.30M Add
Q4 2024 300.00K $5.64M Reduce
Q4 2025 70.00K $4.65M New
Q1 2026 200.00K $12.54M Add
Q2 2026 150.00K $12.23M Reduce
Q3 2026 425.00K $27.82M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ARWR and 13F data

ARWR (ARROWHEAD PHARMACEUTICALS IN) is a Health Care company. 43 other funds we track also report a position in ARWR — the largest reported positions include Avoro Capital Advisors LLC (US$925.6M), FRED ALGER MANAGEMENT, LLC (US$269.1M), BAKER BROS. ADVISORS LP (US$162.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ARWR

All ARWR fund holders →

FAQ

How long has Affinity Asset Advisors, LLC held ARWR?

Affinity Asset Advisors, LLC has disclosed ARWR holdings in 8 of the last 11 reported quarters, going back to Q1 2024.

What is Affinity Asset Advisors, LLC's current position in ARWR?

As of Q3 2026, Affinity Asset Advisors, LLC holds 425.00K shares of ARWR (ARROWHEAD PHARMACEUTICALS IN), valued at $27.82M, representing 1.30% of its reported portfolio and ranking #21.

Has Affinity Asset Advisors, LLC been buying or selling ARWR?

In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC increased its position in ARWR. The position peaked in Q3 2026 at 425.00K shares.

Which other funds hold ARWR?

Other major institutional holders of ARWR include Avoro Capital Advisors LLC, FRED ALGER MANAGEMENT, LLC, BAKER BROS. ADVISORS LP, among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.